About Tizona

Tizona is applying novel scientific insights to change the course of cancer progression and relapse

Our Leadership Team

We believe success comes from a team of cross-functional experts focused on a common vision. For us, it is improving treatment outcomes for people with cancer. Our employees, leadership, Board of Directors, advisors, partners and investors live it. We hope one day, so will patients.

Leadership

Scott Clarke

Chief Executive Officer

Courtney Beers, PhD

Chief Scientific Officer

John Corbin, PhD

Chief Technology Officer

Joyson Karakunnel, MD

Chief Medical Officer

Christine O’Brien

Chief Operating Officer

Shelly Pinto

Vice President, Finance & Controller

Board of Directors

Luke Evnin, PhD

Chair, Tizona Therapeutics & Managing Director, MPM Capital

Scott Clarke

CEO, Tizona Therapeutics

Nina Kjellson

General Partner, Canaan Partners

Pablo J. Cagnoni, MD

CEO, Rubius Therapeutics

Shelley Chu, MD, PhD

Partner, Abingworth

Dan Hicklin, PhD

Co-founder & former CEO, Potenza Therapeutics

Dan Spiegelman

EVP & CFO, BioMarin Pharmaceutical

Scientific Co-founders & Advisory Board

Investors

mpm logo

canaan logo

abingworth logo

interwest logo

lightstone ventures logo

abbvie logo

amgen logo

astellas logo

Partnering with Tizona

We are developing cancer treatments that have the potential to be first- and best-in-class treatments, and core components of immunotherapy combination regimens. We are interested in collaborations with pharmaceutical and biotech companies as well as academic institutions around the world to jointly discover and develop treatments that will improve outcomes for cancer patients. Currently we are engaged in partnering/in-licensing discussions related to our existing programs. For additional information on partnering with Tizona, please contact our business development team at bd@tizonatx.com.